Establishment of proton beam therapy for hepatocellular carcinoma
Establishment of proton beam therapy for hepatocellular carcinoma
批准号:
06670518
负责人:
MATSUZAKI Yasushi
金额:
$1.28万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for General Scientific Research (C)
财政年份:
1994
资助国家:
日本
项目状态:
已结题
起止时间:
1994 至 1995
中文摘要
点击翻译按钮获取中文摘要
英文摘要
We here report the long-term (4years) effects of proton irradiation for HCC,in comparison with that of Lipiodol-targeted chemotherapy (1-TAI), in order to clarify the role of this new therapy for the treatment of HCC.[Materials and Methods] Informed consent was obtained from 48 HCC patients. 75 HCC lesions in the 48 patients which were treated with either proton irradiation alone (Mono : 46 lesions) or with Lipiodol-targeted chemotherapy (1-TAI) plus proton irradiation (Combi : 29 lesions) were included in the analysis. Proton beam was provided by the cynclotoron of the National Laboratory for High Energy Physics (KEK). Total amount of 75 Gy (mean) of the proton beam was targeted to HCC,which ranged from 1 to 12cm in size. The results from these patients were compared with those from 42 patients (65 HCC lesions) treated with 1-TAI alone (1-TAI group), whose background did not differ from the proton groups. All tumor was followed up by CAT scan and ultrasonography. [Results] 1) : After … More 1 yr, the reduction of tumor size was observed in 40 out of 46 lesions (87%) in Mono, 21 out of 29 lesions (72%) in Combi, compared with 30 of 65 lesions (46%) in 1-TAI group. After 2 yrs, size reduction was seen in 11 of 12 (92%) in Mono, 10 of 10 (100%) in Combi and 10 of 16 (63%) in 1-TAI group. After 4 yrs, size reduction was seen in 1 of 1 (100%) in Mono, 3 of 3 (100%) in Combi and 2 of 3 (67%) in 1-TAI group. 2) : Local tumor control rate (no local recurrence) was significantly higher in the proton groups (Mono and Combi) than in the 1-TAI group. By Kaplan and Meier's methods, cumulative local tumor control rates, at the end of 1st yr : 97% for both Mono and Combi, 70% for 1-TAI group, at the end of 4th yr : 60% for Mono, 90% for Combi, 30% for 1-TAI.3) : Survival rate was also significantly higher in the proton groups than in the 1-TAI group during follow-up period. Cumulative survival rates at the end of 2nd and 4th yrs, were 87%, 74% for the proton groups, and 74%, 45% for the 1-TAI group, respectively. 4) : Excellent QOL was maintained in all cases treated with proton therapy during observation period. [Conclusion] HCC patients treated with proton irradiation showed more excellent local tumor control as well as better survival and QOL,in comparison with 1-TAI,which lasted for at least 4 yrs. This therapy is safe and has a special merit of excellent QOL during the treatment without any complaints. Advantages of this methods are the availability for deep-seated tumor, patient with serious complications. Less
期刊论文(40)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
松崎靖司: "切除不可能肝癌に対する新しい陽子線照射療法" 日本内科学会雑誌. 83. 1567-1569 (1994)
Yasushi Matsuzaki:“不可切除肝癌的新质子放射疗法”日本内科学会杂志 83. 1567-1569 (1994)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Chiba, T. et al.: "The role of previous hepatitis B virus infection and heavy smoking in hepatitis C virus-related hepatocellular carcinoma." Ame J Gastroenterol. (in press). (1996)
Chiba, T. 等人:“既往乙型肝炎病毒感染和大量吸烟在丙型肝炎病毒相关肝细胞癌中的作用。”
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Matsuzaki Y.,et al.: "A new effective and safe therapeutic option using proton irradiation for hepatocellular carcinoma" Gastroenterology. 106. 1032-1041 (1994)
Matsuzaki Y. 等人:“使用质子照射治疗肝细胞癌的一种新的有效且安全的治疗选择”胃肠病学。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Chiba, T. et al.: "A multivariate analysis of risk factors for hepatocellular carcinoma in patients with hepatitis C virus-related liver cirrhosis" J Gastroenterol. (in press). (1996)
Chiba, T. 等人:“丙型肝炎病毒相关肝硬化患者肝细胞癌危险因素的多变量分析”J Gastroenterol。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Matsuzaki Y, et al: "New effective treatment using proton irradiation for unresectable hepatocellular carcinoma." Internal Medicine. 34(印刷中). (1995)
Matsuzaki Y 等人:“使用质子照射治疗不可切除的肝细胞癌的新有效疗法”,34(出版中)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 20 条
Invasive metabolic markers for evaluation of host factor on the pathological progress of hepatitis C patients
-
批准号:23590992
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.66万
-
财政年份:2011
-
负责人:MATSUZAKI Yasushi
-
依托单位:
Development of a novel therapy targeting new intracellular receptors for the treatment of malignant melanoma
-
批准号:21791057
-
项目类别:Grant-in-Aid for Young Scientists (B)
-
资助金额:$2.83万
-
财政年份:2009
-
负责人:MATSUZAKI Yasushi
-
依托单位:
Development of a novel sonodynamic therapy for skin cancers
-
批准号:19790769
-
项目类别:Grant-in-Aid for Young Scientists (B)
-
资助金额:$1.39万
-
财政年份:2007
-
负责人:MATSUZAKI Yasushi
-
依托单位:
Chemoprevention of hepatocellular carcinoma by dehydroepiandrosterone and its derivatives
-
批准号:15390225
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$6.27万
-
财政年份:2003
-
负责人:MATSUZAKI Yasushi
-
依托单位:
Suppressive effect of ursodeoxycholic acid on type IIA phospholipase A2 expression in HepG2 cells.
-
批准号:12670457
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.11万
-
财政年份:2000
-
负责人:MATSUZAKI Yasushi
-
依托单位:
The Chemopreventive Role of Ursodeoxycholic Acid in Colon Cancer Model : Suppressive Effects on Enhanced Group II Phospholipase A2 Expression
-
批准号:08670555
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.41万
-
财政年份:1996
-
负责人:MATSUZAKI Yasushi
-
依托单位:
Elucidation of pathogenesis and UDCA effect mechanisms in primary biliary cirrhosis
-
批准号:04670407
-
项目类别:Grant-in-Aid for General Scientific Research (C)
-
资助金额:$1.34万
-
财政年份:1992
-
负责人:MATSUZAKI Yasushi
-
依托单位:
海外基金